Pavurutamab
As of the edition of 20 October 2026, Pavurutamab is an antibody: stopped in 2025; acts on TNFRSF17.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody
- Registered trials
- 3, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TNFRSF17 | Tumor necrosis factor receptor superfamily member 17 | Q02223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 2 | 0 | 0 | 2 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials |